Cannex Capital

Cannara Biotech (USD-listed) carries a Neutral rating, with a composite score of 44 out of 100 and a conviction reading of 2 of 5. Four pillars feed the composite in fixed weights (35/25/25/15 for fundamentals, regulatory, market, and editorial), and no clause of the score is hidden from the reader. Regulatory carries this profile, printing 58 and setting the ceiling on the composite. The editorial pillar sits at 30, and is the main drag on the composite.

The scoring inputs are concrete: reported revenue growth of -19.5 percent year over year, an operating margin of -8.2 percent, gross margin of 40.2 percent, a market cap near 3 million, a jurisdictional posture reading of 80. Together they explain most of the pillar mix. The scoring pipeline pulls only from primary regulatory filings, licensed fundamentals data, institutional pricing feeds, and CIN newsroom coverage, and each pillar exposes its own inputs. This lets Cannara Biotech (USD-listed) be lined up against the global cannabis coverage universe on identical inputs, with refresh cadence tied directly to primary-source ingest.

Filing cadence and jurisdictional posture remain the primary drivers, with regulatory contributing 58. A sustained lift in filing frequency across the trailing 90 days combined with zero enforcement events would tighten the Neutral conclusion.